Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation

Blood

Volumn 107, Issue 5, 2006, Pages 2200-2207

  Chien, Jason W ^a   Lue, Ping Zhao ^b   Hansen, John A ^b   Wen, Hong Fan ^b   Parimon, Tanyalak ^b   Clark, Joan G ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; GENE PRODUCT;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BACTERICIDAL PERMEABILITY INCREASING GENE; COHORT ANALYSIS; CONTROLLED STUDY; DONOR; EPITHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENETIC VARIABILITY; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

EID: 33344466469     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2338     Document Type: Article

References (85)

1. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168:208-214.
2. Tait RC, Burnett AK, Robertson AG, et al. Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease. Int J Radiat Oncol Biol Phys. 1991;20:1219-1227.
3. Beinert T, Dull T, Wolf K, et al. Late pulmonary impairment following allogeneic bone marrow transplantation. Eur J Med Res. 1996;1:343-348.
4. Schwarer AP, Hughes JM, Trotman-Dickenson B, Krausz T, Goldman JM. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation. 1992;54:1002-1008.
5. Duncker C, Dohr D, Harsdorf S, et al. Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome. Bone Marrow Transplant. 2000;25:1263-1268.
6. Curtis DJ, Smale A, Thien F, Schwarer AP, Szer J. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;16:169-173.
7. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for air-flow obstruction in recipients of bone marrow transplants. Ann Intern Med. 1987;107:648-656.
8. Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention (review). Semin Hematol. 2002;39:15-22.
9. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359:2078-2083.
10. Ferrara JLM, Deeg HJ. Graft-versus-host disease (review). N Engl J Med. 1991;324:667-674.
11. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med. 1992;175:405-413.
12. Cooke KR, Krenger W, Hill G, et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood. 1998;92:2571-2580.
13. Jadus MR, Websic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant. 1992;10:1-14.
14. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964-2968.
15. Heinrich J, Gehring U, Douwes J, et al. Pets and vermin are associated with high endotoxin levels in house dust. Clin Exp Allergy. 2001;31:1839-1845.
16. Gereda JE, Klinnert MD, Price MR, Leung DY, Liu AH. Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol. 2001;107:790-796.
17. Michel O, Kips J, Duchateau J, et al. Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med. 1996;154:1641-1646.
18. Park JH, Gold DR, Spiegelman DL, Burge HA, Milton DK. House dust endotoxin and wheeze in the first year of life. Am J Respir Crit Care Med. 2001;163:322-328.
19. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med. 2000;162(pt 1):1355-1360.
20. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002;26:602-609.
21. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol. 2002;26:152-159.
22. Kline JN, Cowden JD, Hunninghake GW, et al. Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care Med. 1999;160:297-303.
23. Becker S, Clapp WA, Quay J, Frees KL, Koren HS, Schwartz DA. Compartmentalization of the inflammatory response to inhaled grain dust. Am J Respir Crit Care Med. 1999;160:1309-1318.
24. Koc S, Leisenring W, Flowers MED, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48-51.
25. Sullivan KM. Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Sciences; 1999:515-536.
26. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disese after allogeneic blood stem cell transplantation. Blood. 1999;94:1465-1470.
27. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
28. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis. 1991;144:1202-1218.
29. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123:659-664.
30. Hsu KH, Jenkins DE, Hsi BP, et al. Ventilatory functions of normal children and young adults - Mexican-American, white, and black. I. Spirometry. J Pediatr. 1979;95:14-23.
31. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet. 1986;73:320-326.
32. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Krug-Iyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74:106-120.
33. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics. 1995;29:311-322.
34. Tost J, Gut IG. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin Biochem. 2005;38:335-350.
35. Fan JB, Oliphant A, Shen R, et al. Highly parallel SNP genotyping. Cold Spring Harbor Symp Quant Biol. 2003;68:69-78.
36. Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A. 2002;99:3902-3907.
37. Elizalde M, Ryden M, van Harmelen V, et al. Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J Lipid Res. 2000;41:1244-1251.
38. Dentener MA, Smit FT, Francot GJ, Buurman WA. Characterization of two monoclonal antibodies directed against bactericidal/permeability-increasing protein. J Infect Dis. 1994;170:1483-1489.
39. Zhao LP, Li SS, Khalid N. A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet. 2003;72:1231-1250.
40. Ralph DD, Springmeyer SC, Sullivan KM, Hackman RC, Storb R, Thomas ED. Rapidly progressive air-flow obstruction in marrow transplant recipients: possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis. 1984;129:641-644.
41. Ostrow D, Buskard N, Hill RS, Vickars L, Churg A. Bronchiolitis obliterans complicating bone marrow transplantation. Chest. 1985;87:828-830.
42. Epler GR, Colby TV. The spectrum of bronchiolitis obliterans. Chest. 1983;83:161-162.
43. Johnson FL, Stokes DC, Ruggiero M, Dalla-Pozza L, Callihan TR. Chronic obstructive airways disease after bone marrow transplantation (review). J Pediatr. 1984;105:370-376.
44. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood. 1988;72:621-627.
45. Chan CK, Hyland RH, Hutcheon MA, et al. Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. Medicine. 1987;66:327-340.
46. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187-191.
47. Bingle CD, Craven CJ. Meet the relatives: a family of BPI- and LBP-related proteins (review). Trends Immunol. 2004;25:53-55.
48. Weiss J. Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria (review). Biochem Soc Trans. 2003;31(pt 4):785-790.
49. Hailman E, Lichenstein HS, Wurfel MM, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994;179:269-277.
50. Tobias PS, Soldau K, Iovine NM, Elsbach P, Weiss J. Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. J Biol Chem. 1997;272:18682-18685.
51. Bernheiden M, Heinrich JM, Minigo G, et al. LBP, CD14, TLR4 and the murine innate immune response to a peritoneal salmonella infection. J Endotoxin Res. 2001;7:447-450.
52. Dentener MA, Francot GJ, Hiemstra PS, et al. Bactericidal/permeability- increasing protein release in whole blood ex vivo: strong induction by lipopolysaccharide and tumor necrosis factor-alpha. J Infect Dis. 1997;175:108-117.
53. Weiss J, Muello K, Victor M, Elsbach P. The role of lipopolysaccharides in the action of the bactericidal/ permeability-increasing neutrophil protein on the bacterial envelope. J Immunol. 1984;132:3109-3115.
54. Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli. J Clin Invest. 1990;86:631-641.
55. Elsbach P, Weiss J. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide (review). Immunobiology. 1993;187:417-429.
56. Greene CM, Carroll TP, Smith SG, et al. TLR-induced inflammation in cystic fibrosis and noncystic fibrosis airway epithelial cells. J Immunol. 2005;174:1638-1646.
57. Monick MM, Yarovinsky TO, Powers LS, et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem. 2003;278:53035-53044.
58. Skerrett SJ, Liggitt HD, Hajjar AM, Ernst RK, Miller SI, Wilson CB. Respiratory epithelial cells regulate lung inflammation in response to inhaled endotoxin. Am J Physiol Lung Cell Mol Physiol. 2004;287:L143-L152.
59. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653.
60. Hollingsworth JW, Chen BJ, Brass DM, et al. The critical role of hematopoietic cells in lipopolysaccharide-induced airway inflammation. Am J Respir Crit Care Med. 2005;171:806-813.
61. Kueppers F, Miller RD, Gordon H, Hepper NG, Offord K. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med. 1977;63:336-342.
62. Higgins M, Keller J. Familial occurrence of chronic respiratory disease and familial resemblance in ventilatory capacity. J Chronic Dis. 1975;28:239-251.
63. Kawakami Y, Irie T, Kishi F, et al. Familial aggregation of abnormal ventilatory control and pulmonary function in chronic obstructive pulmonary disease. Eur J Respir Dis. 1981;62:56-64.
64. DeMeo DL, Carey VJ, Chapman HA, et al. Familial aggregation of FEF(25-75) and FEF(25-75)/ FVC in families with severe, early onset COPD. Thorax. 2004;59:396-400.
65. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med. 1998;157:1770-1778.
66. Givelber RJ, Couropmitree NN, Gottlieb DJ, et al. Segregation analysis of pulmonary function among families in the Framingham Study. Am J Respir Crit Care Med. 1998;157:1445-1451.
67. Redline S, Tishler PV, Rosner B, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. Am J Epidemiol. 1989;129:827-836.
68. Redline S, Tishler PV, Lewitter FI, Tager IB, Munoz A, Speizer FE. Assessment of genetic and nongenetic influences on pulmonary function. A twin study. Am Rev Respir Dis. 1987;135:217-222.
69. Webster PM, Lorimer EG, Man SF, Woolf CR, Zamel N. Pulmonary function in identical twins: comparison of nonsmokers and smokers. Am Rev Respir Dis. 1979;119:223-228.
70. Silverman EK, Mosley JD, Palmer LJ, et al. Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes. Hum Mol Genet. 2002;11:623-632.
71. Silverman EK, Palmer LJ, Mosley JD, et al. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet. 2002;70:1229-1239.
72. Palmer LJ, Celedon JC, Chapman HA, Speizer FE, Weiss ST, Silverman EK. Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease [erratum appears in Hum Mol Genet. 2003;12:2085]. Hum Mol Genet. 2003;12:1199-1210.
73. DeMeo DL, Celedon JC, Lange C, et al. Genome-wide linkage of forced mid-expiratory flow in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:1294-1301.
74. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941-3946.
75. Middleton PG, Taylor PRA, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92:3943-3948.
76. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;100:3908-3918.
77. Lin M-T, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003;349:2201-2210.
78. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med. 2003;168:628-632.
79. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005;171:780-785.
80. Parimon T, Madtes DK, Au DH, Clark JG, Chien JW. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med. 2005;172:384-390.
81. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 2004;305:869-872.
82. Swarbrick MM, Vaisse C. Emerging trends in the search for genetic variants predisposing to human obesity (review). Curr Opin Clin Nutr Metab Care. 2003;6:369-375.
83. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361:1671-1676.
84. Morral N, Dork T, Llevadot R, et al. Haplotype analysis of 94 cystic fibrosis mutations with seven polymorphic CFTR DNA markers [erratum appears in Hum Mutat. 1996;8:295-296]. Hum Mutat. 1996;8:149-159.
85. Horwitz AH,Ammons WS, Bauer RJ, et al. rBPI(10-193) is secreted by CHO cells and retains the activity of rBPI21. J Endotoxin Res. 2004;10:97-106.